BNP (B-type Natriuretic Peptide) vs DSIP
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
BNP (B-type Natriuretic Peptide)
BNP is a cardiac neurohormone released primarily by ventricles in response to volume/pressure overload. It's a major biomarker for heart failure and has therapeutic applications as nesiritide.
Full details →DSIP
Delta Sleep-Inducing Peptide is a neuropeptide that promotes delta wave sleep, the deepest and most restorative phase of the sleep cycle.
Full details →Side-by-Side Comparison
| Aspect | BNP (B-type Natriuretic Peptide) | DSIP |
|---|---|---|
| Mechanism | Similar to ANP - activates NPR-A receptors to produce vasodilation, natriuresis, and RAAS suppression. Released in response to ventricular wall stress. | Modulates sleep-wake cycles by affecting sleep spindles and delta rhythms. May also influence stress hormones and have analgesic properties. |
| Typical Dosage | Nesiritide (recombinant BNP): 2mcg/kg IV bolus followed by 0.01mcg/kg/min continuous infusion for acute decompensated heart failure. | Typical dosing: 100-300mcg administered 30 minutes before sleep. Some protocols use it cyclically. |
| Administration | Intravenous administration only. Used in acute care settings for heart failure. BNP levels also used diagnostically. | Subcutaneous or intramuscular injection before bedtime. Some users report better results with cyclical use. |
| Side Effects | Hypotension (common and dose-limiting), headache, nausea, and potential renal function worsening in some patients. | May cause grogginess upon waking, vivid dreams, or temporary headaches. |
| Best For |
What They Have in Common
Both BNP (B-type Natriuretic Peptide) and DSIP are commonly used for: